LDN Social Media
Get connected with us on social networks
LDN in Clinical Practice - Andrew McCall, MB, ChB, DFM (2021 Conference) (LDN, low dose naltrexone)
Dr. McCalL presents his practice’s experience using Low Dose Naltrexone for pain management and inflammation, Post Viral Fatigue, CFS/ME, Rheumatoid Arthritis, and Idiopathic Dystonia. Dr. McCall presents 8 different cases. He includes current research and other case papers to support the findings his practice has had.
“Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study”, PLOS One, 2019, showed significant and clinically relevant reduction in anti inflammatories and other prescribed medications for RA patients who used LDN in comparison with those who did not.
In a case study paper, Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris, 2017, describes for LPP patients treated with LDN of 3mgs per day provided benefit in four patients including reduction of symptoms of clinical evidence of inflammation of their scalp and disease progression.
This article from PubMed, No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study, 2020, does not support the efficacy LDN in treating hyperthyroidism. Limitations of this study are stated: no control group, data collection didn’t demonstrate if a patient took LDN short-term, long-term, or not at all. Dr. McCall states that his clinic’s experience has demonstrated that LDN has enabled a significant number of patients to reduce their thyroid medication.
The research article “Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy”, published in the International Journal of Oncology, 2016 supports the idea that LDN possesses anticancer activity.
In a recent study, published in International Immunopharmacology, vol. 79, February 2020, Naltrexone was found to relieve inflammation in the collagen-induced arthritis in rats.
KEYWORDS: Low Dose Naltrexone, LDN, anti inflammatory, Rheumatoid Arthritis, RA, dystonia, eczema, fatigue, Post Viral Fatigue, ME/CFS, Chronic Fatigue Syndrome, pain, immunotherapy, MS, Multiple Sclerosis, cancer, Naltrexone, opioids, pain management, inflammation, arthritis
This is a summary of the presentation. Click on the video for full information.